I'm less optimistic and think this is a red herring, I mean big pharma acquire clinical phase 2 success drugs every day of the week, why is this one awaiting FDA approval based on merely updated instructions still deemed insufficiently attractive? Clearly I'm missing something.
I'm less optimistic and think this is a red herring, I mean big...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $401.6M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38882 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 79000 | 4 |
View Market Depth
| Last trade - 09.50am 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
26.0¢ |
Change
0.000 ( 1.40 %) |
||||
| Open | High | Low | Volume | ||
| 26.0¢ | 26.5¢ | 26.0¢ | 189377 | ||
| Last updated 10.11am 16/05/2024 ? | |||||
| BOT (ASX) Chart |
Day chart unavailable